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Epstein–Barr virus: LMP1 masquerades as an active receptor
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The Epstein–Barr virus protein LMP1 is essential for
transformation of resting B cells by the virus, but how it
works is unclear. Recent results suggest that LMP1 acts
as a constitutively active receptor that shares certain
characteristics with members of the tumour necrosis
factor receptor superfamily.
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Epstein–Barr virus (EBV) is a human γ-herpesvirus that is
associated with several types of malignancy. EBV infects
resting B cells and stimulates their proliferation via the
coordinated expression of a number of ‘latent cycle’ genes,
so-called because they are associated with latent virus
infection. This process can be studied in vitro, where B
cell infection leads to the outgrowth of virus-transformed
lymphoblastoid cell lines expressing the nuclear antigens
EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and
EBNA-LP, and the latent membrane proteins LMP1,
LMP2A and LMP2B. At least five of these proteins
appear to be essential for growth transformation: the virus-
genome-maintenance protein EBNA1, the transcriptional
activators/regulators EBNA2, EBNA3A and EBNA3C,
and the pleiotropic effector protein LMP1 [1].
LMP1 has attracted intense interest ever since it was found
to induce the oncogenic transformation of rodent fibroblast
cell lines. The multiple phenotypic effects of LMP1
expression have been most closely described, however, in
human B lymphoma cell lines; they include cell aggrega-
tion, up-regulation of cell-surface markers such as CD40
and CD54, the activation of several cytokine genes, and the
induction of cell-survival proteins such as Bcl2, BclxL,
Mcl1 and A20. With hindsight, it is interesting to reflect
how many of these changes recapitulate those induced in
normal B cells by CD40 ligation. Now, as a spate of recent
papers testify, the LMP1 and CD40 signalling pathways
are becoming ever more closely intertwined.
Structurally, LMP1 is a 63 kDa phosphoprotein with a
short (23 amino acid) amino-terminal sequence, six mem-
brane-spanning domains (residues 24–186) and a long
carboxy-terminal cytoplasmic tail (residues 187–386).
LMP1 appears to oligomerise in the membrane, and the
topology of two adjacent molecules is shown schematically
in Figure 1. Genetic analysis has shown that both the trans-
membrane and carboxy-terminal regions are required for
LMP1-induced phenotypic changes in transfection assays,
and for B-cell transformation by the virus itself. Interest-
ingly, a recombinant virus expressing a truncated form of
LMP1 with the amino terminus/transmembrane domain
and only the 45 most membrane-proximal residues of the
carboxy-terminal tail (residues 1–231) could induce B-cell
growth for several weeks in vitro, although the infected
cells remained fibroblast-dependent and proliferation
eventually ceased [2]. This was the first suggestion that the
LMP1 carboxyl terminus contained functionally distinct
domains, a theme upon which the subsequent molecular
dissection of LMP1 signalling pathways has elaborated.
LMP1 expression leads to the rapid activation of the tran-
scription factor NFκB, and transient assays with deletion
mutants identified two ‘carboxy-terminal activating
regions’ that contributed to this effect — the membrane-
proximal CTAR1 (residues 194–232) and the membrane-
distal CTAR2 (residues 351–386) [3,4]. Although CTAR1
corresponded to what appeared to be the major effector
domain for cell transformation, CTAR2 was the stronger
NFκB-activating domain, accounting for 70–80% of the
induction in a variety of cell types. Another more recent
finding [5] links LMP1 to activation of c-Jun amino-termi-
nal kinase (JNK, also known as stress-activated protein
kinase, SAPK). JNK activation leads directly to induction
of the transcription factor AP1, a dimer composed of
members of the Jun or Fos family, which has been impli-
cated in growth control in a number of contexts. 
JNK activation by LMP1 occurs with kinetics that mirror
NFκB activation [6]. When analysed by transient transfec-
tion in the human embryonic kidney cell line 293, this
JNK/AP1 induction maps entirely to CTAR2 [5,6]. The
results of recombinant virus experiments involving LMP1
mutants make it clear that CTAR2 has no B-cell growth
transforming ability in the absence of the CTAR1 domain.
However, the link between CTAR2 and transcription
factor activation is consistent with this distal domain
having an important auxiliary role in the transformation
process. Certainly, in B-cell lines transformed with a mini-
EBV construct carrying a tetracycline-conditional LMP1
gene, re-entry of cells into cycle upon re-induction of
LMP1 expression correlates closely with the kinetics of
JNK activation [5].
Against this background, what do we know about the
molecular interactions through which CTAR1 and CTAR2
transmit their signals? The seminal paper of Mosialos and
colleagues [7] first showed, using yeast two-hybrid analysis,
that the carboxy-terminal half of LMP1 interacts with a
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molecule of the tumour necrosis factor (TNF) receptor-
associated factor (TRAF) family. This immediately drew a
parallel between LMP1 and members of the TNF receptor
superfamily, such as TNFRII and CD40, which also bind
TRAFs via their intracytoplasmic carboxy-terminal
domains. TRAF binding by LMP1 mapped within the
CTAR1 region and involved a PXQXT motif (residues
204–208; where X can be any amino acid) that was also
present in the carboxy-terminal sequences of CD40 and
certain other TNF receptor family members.
LMP1 showed strongest interactions with TRAF3 and
TRAF1, but was also capable of binding TRAF2 [8,9].
This was of particular interest, as TRAF2 is known to
mediate NFκB activation by CD40 and TNFRII. An
equivalent role for TRAF2 in LMP1 signal transduction
was confirmed when it was found that CTAR1 induction
of NFκB could be blocked by a dominant-negative
mutant form of TRAF2 [8–10]. The signalling compo-
nents that link CTAR1/TRAF2 to NFκB are currently
unknown. By analogy with the events following TNFR
activation, however, a TRAF2-bound kinase called
NFκB-inducing kinase (NIK) may be involved. NIK acti-
vation leads to phosphorylation of IκB kinase (IKK),
which in turn induces phosphorylation of IκBα and the
subsequent release of functional NFκB (reviewed in [11]
and illustrated in Figure 1). Furthermore, recent work has
shown that CTAR1 binds another TRAF species,
TRAF5, which can also activate NFκB [12].
Until recently, the molecular connections at CTAR2 have
been a matter for speculation. No direct interaction was
detectable between CTAR2 and any of the TRAF
species. Interestingly, however, a dominant-negative
mutant form of TRAF2 partially inhibited CTAR2-
induced NFκB activation, as did other TRAF2-interact-
ing proteins, such as TANK/I-TRAF and A20 [8,10].
These phenomena could now be explained by recent
work in which yeast two-hybrid and biochemical analyses
showed that CTAR2 binds to the TNFR-associated
death domain (TRADD) protein [13]. TRADD is known
by virtue of its interaction with TNFRI, where it acts as a
platform for the recruitment of other proteins; one of
these is TRAF2 and this interaction leads to both NFκB
and JNK activation [14]. 
The above findings are most consistent with the view that
the transmission of signals from CTAR2 occurs via a
CTAR2–TRADD–TRAF2 complex. The signalling com-
ponents downstream of this complex are not yet known,
but, by analogy with TNFRI signalling pathways, it is pos-
sible that the NFκB and JNK activating signals bifurcate
at the level of TRAF2. The NIK–IKK–IκΒ pathway could
lead to NFκB activation, whereas the pathway leading to
JNK may involve a recently described germinal centre
kinase-related (GCKR) protein that is downstream of
TRAF2 but upstream of SEK–JNK–AP1 (Figure 1) [15].
Bifurcation of the CTAR2 signalling pathway must occur
because, as a recent study shows [6], blockade of NFκB
activation by a constitutively active IκBα mutant does not
affect the LMP1–JNK connection and, conversely,
expression of a dominant-negative form of SEK blocks
JNK but not NFκB activation.
Figure 1
The pathways by which the EBV protein LMP1 is thought to signal
inside cells. LMP1 has a short cytoplasmic amino terminus, six
transmembrane domains (which confer aggregation at the cell
membrane) and a long cytoplasmic carboxy-terminal tail containing two
effector domains, CTAR1 and CTAR2. The CTAR1 domain, which is
essential for EBV-induced B-cell transformation, binds TRAF1, TRAF2
and TRAF3; TRAF2 mediates NF-κB activation, presumably via the
NIK–IKK–IκB pathway. The CTAR2 domain, which is important for
long-term outgrowth of infected B cells, binds TRADD, and this is
thought to recruit TRAF2, leading to both NFκB and JNK–AP1
activation through a bifurcating pathway; induction of NFκB may also
occur via the NIK–IKK–IκB pathway, while the connection to
SEK–JNK–AP1 activation may be via the recently described GCKR
protein.
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A key distinction between LMP1 and the TNFR family
members is that the activity of the viral protein is consti-
tutive, rather than dependent upon the binding of a
cognate ligand. The strong inference from early work on
the distribution of LMP1 mutants within cells was that
LMP1 function is dependent upon oligomerisation in the
membrane, presumably via intermolecular associations of
the six membrane-spanning domains. This has now been
elegantly confirmed in experiments with chimeric mole-
cules, in which the extracellular and transmembrane
regions of CD2, CD4 or a member of the TNFR super-
family, NGFR, have been linked to the intracytoplasmic
carboxyl terminus of LMP1 — LMP1-mediated sig-
nalling is now seen only following antibody-induced or
ligand-induced aggregation of the chimaera [16,17]. Con-
versely, the carboxy-terminal tail of CD40 can be ren-
dered constitutively active by linkage to the
amino-terminal and hydrophobic domains of LMP1, and
indeed this chimaera mimics many aspects of wild-type
LMP1 function [6,18].
EBV, particularly its product LMP1, thus provides a
telling example of how ancient viruses can usurp cellular
pathways of central physiological importance for their own
ends. The pursuit of LMP1 signalling will no doubt con-
tinue to provide an invaluable side entrance into the
complex biology of the TNFR/CD40 family.
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